Clinical trials: Cancer Breast
HER2 Negative Breast Cancer
Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer
The investigators propose a randomized phase II study evaluating the pCR and toxicity profiles of combination eribulin/cyclophosphamide (ErC) and docetaxel /cyclophosphamide (TC) as neoadjuvant therapy for locally advanced…
- Trial name
- NCT01527487
- Testing
- Eribulin, Cyclophosphamide, Docetaxel
- Where
- 15 sites in United States
- Volunteers
- 76 people
- Sponsor
- SCRI Development Innovations, LLC
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer
Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery
This phase II trial is studying how well giving entinostat and anastrozole together works in treating postmenopausal women with triple-negative breast cancer that can be removed by surgery.
- Conditions
- Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage I Breast Cancer
- Trial name
- 0927GCC (NCT01234532)
- Testing
- entinostat, anastrozole, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Maryland, Baltimore
Neoplasms, Breast
Treatment With Pazopanib for Neoadjuvant Breast Cancer
The purpose of this study is to determine whether the treatment of a doxorubicin in combination with cyclophosphamide followed by a combination of pazopanib in combination with paclitaxel prior to surgery results in a…
- Trial name
- NCT00849472
- Testing
- doxorubicin + cyclophosphamide, paclitaxel + pazopanib, surgery
- Where
- 143 sites in United States, Canada
- Volunteers
- 101 people
- Sponsor
- GlaxoSmithKline
Breast Neoplasms
Partial Breast Irradiation (PBI) for Selected Patients With Early Breast Cancer
This study investigates the feasibility and safety of delivering radiation therapy only to part of the breast, (the tumor bed and selected areas) rather than the whole breast, for patients with early stage breast cancer.
- Trial name
- NCT00325598
- Testing
- Partial Breast Irradiation (PBI)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Washington University School of Medicine
Metastatic Breast Cancer
Standard Versus Continuous Capecitabine in Advanced Breast Cancer
Capecitabine is active in metastatic breast cancer but the conventional schedule (1250 mg/m2/12 hr 2 weeks on, one week off) produces grade 2 or greater hand and foot syndrome in up to 50% of patients leading to those reductions.
- Trial name
- NCT00418028
- Testing
- Capecitabine
- Where
- Spain
- Volunteers
- 195 people
- Sponsor
- Hospital San Carlos, Madrid
Breast Cancer
Real-world Treatment Patterns of Endocrine Based Therapy Among Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor-2-negative (HR+/HER2-) Advanced Breast Cancer: An Analysis of Administrative Claims Data in Japan
This is a retrospective observational study focusing on patients diagnosed with advanced breast cancer(ABC) in Japan using de-identified claim data from Medical Data Vision (MDV) database.
- Trial name
- NCT05153187
- Where
- Japan
- Volunteers
- 1,170 people
- Sponsor
- Pfizer
Solid Tumor
A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.
This was a clinical study with an orally administered drug, BDTX-189 in participants with advanced solid tumors that had select mutations or alterations in human epidermal growth factor receptor 2 (HER2/ErbB2) genes or epidermal…
- Trial name
- MasterKey-01 (NCT04209465)
- Testing
- BDTX-189
- Where
- 38 sites in United States, Denmark and 2 more
- Volunteers
- 91 people
- Sponsor
- Black Diamond Therapeutics, Inc.
Breast Cancer
Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00616967
- Testing
- carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, vorinostat
- Where
- 5 sites in United States
- Volunteers
- 68 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recurrent Breast Carcinoma, Stage IV Breast Cancer
Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer
This phase II trial studies how well erlotinib hydrochloride and bevacizumab work in treating patients with stage IV breast cancer.
- Trial name
- NCT00054132
- Testing
- Bevacizumab, Erlotinib Hydrochloride, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
A Study of Pertuzumab in Participants With Metastatic Breast Cancer
This study will evaluate the efficacy and safety of pertuzumab (rhuMAb 2C4) in participants with metastatic breast cancer which has progressed during or after standard chemotherapy and which is not amenable to curative therapy.
- Trial name
- NCT02491892
- Testing
- Pertuzumab
- Where
- 18 sites in Australia, Belgium and 6 more
- Volunteers
- 79 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer
The majority pf breast cancers present as ER-positive, many of which are able to be targeted with multiple hormonal therapies. Altering ER-negative tumors to increase ER expression has the potential to benefit patients by making…
- Trial name
- NCT00726180
- Testing
- trastuzumab (Herceptin®)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Michigan Rogel Cancer Center
Metastatic Breast Cancer
Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients
This is a single-arm, open-label, phase I/II study. In the phase I, patients with Human Epidermal Growth Factor Receptor 2 (HER2) positive MBC will be treated with paclitaxel, trastuzumab and increasing doses of dasatinib to…
- Trial name
- NCT01306942
- Testing
- Dasatinib, Trastuzumab, Paclitaxel
- Where
- 8 sites in Spain
- Volunteers
- 37 people
- Sponsor
- Spanish Breast Cancer Research Group
Breast Cancer
Pilot Clinical Evaluation of a Microwave Imaging System for Breast Cancer Detection
The trialed investigational medical imaging device is a low-power microwave breast imaging system for cancer screening purposes. It is an active device which uses non-ionizing radiation.
- Trial name
- NCT05757427
- Testing
- Wavelia #2
- Where
- Ireland
- Volunteers
- 73 people
- Sponsor
- MVG Industries SAS
Breast Cancer
Narrative Visualization for Breast Cancer Survivors' Physical Activity
This study tests the feasibility and acceptability of a physical activity intervention that combines use of a wearable activity monitor with a scrapbook.
- Trial name
- NCT03612596
- Testing
- Narrative visualization, Standard self-regulation
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
Her2 Negative Breast Cancer Patients
Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer
To determine whether the combination MM-121 + Exemestane in ER+ and/or PR+ breast cancer patients is more effective than Exemestane alone
- Trial name
- NCT01151046
- Testing
- MM-121, Exemestane
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 118 people
- Sponsor
- Merrimack Pharmaceuticals
Bone Metastases, HER2-positive Breast Cancer
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
This pilot clinical trial studies how well copper Cu 64-tetra-azacyclododecanetetra-acetic acid (DOTA)-trastuzumab positron emission tomography (PET) works in predicting response to treatment with ado-trastuzumab emtansine in…
- Conditions
- Bone Metastases, HER2-positive Breast Cancer, Liver Metastases, Lung Metastases
- Trial name
- NCT02226276
- Testing
- fludeoxyglucose F 18, positron emission tomography, computed tomography
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
Breast Neoplasm Female
Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response
The hypothesis of this study is that paclitaxel levels increase chromosomal instability (CIN) in tumors and this is lethal to tumors that have pre-existing CIN. Treatment will be administered on an outpatient basis.
- Trial name
- NCT03096418
- Testing
- Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Wisconsin, Madison
Neoplasms, Breast
Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer
This was a multicenter, open-label, Phase II study in subjects with Human epidermal growth factor receptor (HER2)-positive metastatic breast cancer who received at least 2 prior lines of anti-HER2-targeted therapies of which at…
- Trial name
- NCT02213042
- Testing
- Lapatinib, Trastuzumab, Aromatase Inhibitors (AIs)
- Where
- 51 sites in United States, Argentina and 10 more
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment
The initial goal of the investigators interdisciplinary group of imagers, oncologists, neurologists, neuro-psychologists, and biostatisticians is to obtain proof of concept pilot data for eventual submission of a National Cancer…
- Trial name
- NCT02317783
- Testing
- [18F]Flutemetamol, [18F]fluoro-2-deoxy-D-glucose (FDG), Functional Magnetic Resonance Imaging (fMRI)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Utah
Breast Cancer
Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer
Patients with moderate to high risk primary breast cancer (Stage II with more than 4 lymph nodes involved with cancer) III or Stage IV (without evidence of disease) will take tetrathiomolybdate (TM) pills for two years.
- Trial name
- NCT00195091
- Testing
- Tetrathiomolybdate
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.